Cargando…

Correlation between PPAR-α methylation level in peripheral blood and atherosclerosis of NAFLD patients with DM

We investigated the correlation between the methylation levels of peroxisome proliferator-activated receptor-α (PPAR-α) in the peripheral blood and atherosclerosis in patients with nonalcoholic fatty liver disease (NAFLD) with diabetes mellitus (DM). A total of 50 normal subjects (group N) and 50 NA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ju, Jianghua, Huang, Qingxian, Sun, Jing, Zhao, Xiaoyun, Guo, Xiuli, Jin, Yongcheng, Ma, Wenjie, Wang, Wenhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795669/ https://www.ncbi.nlm.nih.gov/pubmed/29456675 http://dx.doi.org/10.3892/etm.2018.5730

Ejemplares similares

Correlation between PPAR-α methylation level in peripheral blood and inflammatory factors of NAFLD patients with DM
por: Ju, Jianghua, et al.
Publicado: (2018)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity
por: Régnier, Marion, et al.
Publicado: (2020)

PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?
por: Theys, Claudia, et al.
Publicado: (2022)

PPARs and Mitochondrial Metabolism: From NAFLD to HCC
por: Mello, Tommaso, et al.
Publicado: (2016)

Insights into the Role of PPARβ/δ in NAFLD
por: Chen, Jiapeng, et al.
Publicado: (2018)

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
por: Montagner, Alexandra, et al.
Publicado: (2016)

TET1 promotes fatty acid oxidation and inhibits NAFLD progression by hydroxymethylation of PPARα promoter
por: Wang, Jingjie, et al.
Publicado: (2020)

Chaetomorpha linum polysaccharides alleviate NAFLD in mice by enhancing the PPARα/CPT-1/MCAD signaling
por: Chu, Xueru, et al.
Publicado: (2022)

Expression of TNF-α and IL-1β in Peripheral Blood of Patients with T2DM Retinopathy
por: Qian, Jin, et al.
Publicado: (2022)

The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases
por: Wójcik-Cichy, Kamila, et al.
Publicado: (2018)

Emergent Properties of the HNF4α-PPARγ Network May Drive Consequent Phenotypic Plasticity in NAFLD
por: Sahoo, Sarthak, et al.
Publicado: (2020)

DNMT1-mediated PPARα methylation aggravates damage of retinal tissues in diabetic retinopathy mice
por: Zhu, Ying, et al.
Publicado: (2021)

Predictive Value of Noninvasive Peripheral Atherosclerosis Measurement for Coronary Artery Disease in Patients with Long T2DM Duration
por: Chen, Wanjiao, et al.
Publicado: (2023)

Sini Decoction Intervention on Atherosclerosis via PPARγ-LXRα-ABCA1 Pathway in Rabbits
por: Ju, Shicong, et al.
Publicado: (2018)

Serum Pentosidine is Associated with Cardiac Dysfunction and Atherosclerosis in T2DM
por: Cao, Yuyan, et al.
Publicado: (2023)

Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs
por: Mukherjee, Anirban Goutam, et al.
Publicado: (2022)

Decreased Iron Ion Concentrations in the Peripheral Blood Correlate with Coronary Atherosclerosis
por: Meng, Heyu, et al.
Publicado: (2022)

Naoxintong Retards Atherosclerosis by Inhibiting Foam Cell Formation through Activating PPARα Pathway
por: Wang, Zeng, et al.
Publicado: (2018)

PPARα Targeting GDF11 Inhibits Vascular Endothelial Cell Senescence in an Atherosclerosis Model
por: Dou, Fangfang, et al.
Publicado: (2021)

Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients
por: Liu, Xiaojie, et al.
Publicado: (2017)

PPARα and PPARβ/δ are negatively correlated with proinflammatory markers in leukocytes of an obese pediatric population
por: Vargas-Sánchez, Karina, et al.
Publicado: (2020)

A Novel Role of Globular Adiponectin in Treatment with HFD/STZ Induced T2DM Combined with NAFLD Rats
por: Ma, Hong, et al.
Publicado: (2014)

The Hepatoprotection by Oleanolic Acid Preconditioning: Focusing on PPARα Activation
por: Wang, Wenwen, et al.
Publicado: (2018)

Correlation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) and Retinoid X Receptor-α (RXR-α) expression with clinical risk factors in patients with advanced carotid atherosclerosis
por: Giaginis, Constantinos, et al.
Publicado: (2011)

HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRα and PPARα dysregulation: implications for HIV-specific pathogenesis of NAFLD
por: Agarwal, Neeti, et al.
Publicado: (2017)

Peripheral blood mononuclear cell mitochondrial copy number and adenosine triphosphate inhibition test in NAFLD
por: Lee, A-Hyeon, et al.
Publicado: (2022)

Metabolomics of the interaction between PPAR-α and age in the PPAR-α-null mouse
por: Atherton, Helen J, et al.
Publicado: (2009)

Identification of a potent NAFLD drug candidate for controlling T2DM-mediated inflammation and secondary damage in vitro and in vivo
por: Samsuzzaman, Md, et al.
Publicado: (2022)

The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD
por: Dixon, Emmanuel D., et al.
Publicado: (2021)

Is the rs1801282 (G/C) Polymorphism of PPAR - Gamma Gene Associated with T2DM in Iraqi People?
por: Al-Naemi, Amjad Hazim, et al.
Publicado: (2018)

Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis
por: Yoo, Hye Jin, et al.
Publicado: (2017)

Endothelial Dysfunction, a Marker of Atherosclerosis, Is Independent of Metabolic Syndrome in NAFLD Patients
por: Narayan, Jimmy, et al.
Publicado: (2020)

PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists
por: Silswal, Neerupma, et al.
Publicado: (2012)

Association of Abdominal Obesity with Atherosclerosis in Type 2 Diabetes Mellitus (T2DM) in Korea
por: Cho, Minho, et al.
Publicado: (2008)

An Ideal PPAR Response Element Bound to and Activated by PPARα
por: Tzeng, John, et al.
Publicado: (2015)

Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis
por: Ruscica, Massimiliano, et al.
Publicado: (2019)

Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance?
por: Alemany-Pagès, Mireia, et al.
Publicado: (2020)

PPARα and Effects of TCE
por: Klaunig, James E., et al.
Publicado: (2007)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pafqto8pgim04ch29pahb4rkdf